Program
Metformin
Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 290 open or running | phase 3since Nov 9, 2005 | Nov 9, 2005 | none ahead |
| Merck | 190 open or running | phase 4since Oct 9, 2009 | Feb 15, 2005 | none ahead |
| Sanofi | 160 open or running | phase 4since Jul 28, 2006 | Sep 30, 2002 | none ahead |
| GlaxoSmithKline | 140 open or running | phase 4since Oct 17, 2005 | Sep 3, 2003 | none ahead |
| Takeda | 120 open or running | phase 4since Sep 17, 2008 | Jul 30, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germany | 90 open or running | phase 4since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| Teva Pharmaceutical Industries | 90 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatris | 80 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| adium | 70 open or running | no phasesince Jun 3, 2026 | Jun 3, 2026 | none ahead |
| LG Chem | 70 open or running | phase 3since Feb 6, 2013 | Aug 22, 2011 | none ahead |
| Novartis | 70 open or running | phase 4since Aug 28, 2010 | Jul 31, 2008 | none ahead |
| elcelyx-therapeutics-inc | 60 open or running | phase 2since Aug 1, 2012 | Aug 1, 2012 | none ahead |
| Torrent Pharmaceuticals | 60 open or running | phase 1since Jul 21, 2009 | Jul 21, 2009 | none ahead |
| dong-wha-pharmaceutical-co-ltd | 50 open or running | phase 1since Aug 5, 2014 | Aug 5, 2014 | none ahead |
| Bristol-Myers Squibb | 40 open or running | phase 4since Oct 22, 2008 | May 3, 2002 | none ahead |
| joint-stock-company-farmak | 40 open or running | phase 1since Nov 8, 2021 | Nov 8, 2021 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 40 open or running | phase 4since Jul 15, 2009 | Jul 15, 2009 | none ahead |
| Pfizer | 40 open or running | phase 1since Dec 15, 2008 | Jan 25, 2006 | none ahead |
| gedeon-richter-plc | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Sun Pharmaceutical Industries | 30 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| aet-laboratories-private-limited | 20 open or running | no phasesince Mar 25, 2022 | Mar 25, 2022 | none ahead |
| agelessrx | 21 open or running | phase 3since Dec 18, 2024 | Oct 26, 2020 | none ahead |
| aspargo-labs-inc | 22 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | none ahead |
| biocinese | 20 open or running | phase 4since Jun 2, 2011 | Apr 27, 2011 | none ahead |
| Boryung Pharmaceutical | 22 open or running | phase 1since Jul 16, 2025 | Jul 16, 2025 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Geropharm | 20 open or running | phase 1since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Handok | 20 open or running | phase 4since Sep 21, 2011 | Sep 21, 2011 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 3since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| Jeil Pharmaceutical | 20 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| nusirt-biopharma | 20 open or running | phase 2since May 28, 2014 | May 28, 2014 | none ahead |
| bio-innova-co-ltd | 11 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Clinique Ovo | 10 open or running | phase 3since Jul 9, 2012 | Jul 9, 2012 | none ahead |
| cortendo-ab | 10 open or running | phase 1since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Daewoong Pharmaceutical | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| dalim-biotech-co-ltd | 10 open or running | phase 1since Jan 29, 2013 | Jan 29, 2013 | none ahead |
| disphar-international-b-v | 10 open or running | phase 1since Aug 14, 2014 | Aug 14, 2014 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| getz-pharma | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| Hamad Medical | 10 open or running | no phasesince Apr 19, 2021 | Apr 19, 2021 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since Jan 23, 2013 | Jan 23, 2013 | none ahead |
| health-clinics-limited | 10 open or running | phase 3since Jul 22, 2014 | Jul 22, 2014 | none ahead |
| ikfe-cro-gmbh | 10 open or running | phase 4since Sep 15, 2010 | Sep 15, 2010 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| Lotus Pharmaceutical | 10 open or running | phase 3since Nov 19, 2010 | Nov 19, 2010 | none ahead |
| nabiqasim-industries-pvt-ltd | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| ozmosis-research-inc | 10 open or running | phase 2since Feb 18, 2011 | Feb 18, 2011 | none ahead |
| pt-pyridam-farma-tbk | 10 open or running | no phasesince Feb 12, 2023 | Feb 12, 2023 | none ahead |
Also a collaborator on its studies: parexel, pt-pharma-metric-labs, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene, Eli Lilly and merck-s-l-spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Oct 5, 2015.
- Dec 18, 2024Phase 3 study in Longevityagelessrx · NCT07092618 · 150 planned · United States
- Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2gedeon-richter-plc · NCT06792968 · 64 enrolled · Russian Federation
- Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2gedeon-richter-plc · NCT06823856 · 64 enrolled · Russian Federation
- Feb 19, 2025nabiqasim-industries-pvt-ltd's first study: phase 4 study in Diabetes MellitusNew to nabiqasim-industries-pvt-ltdnabiqasim-industries-pvt-ltd · NCT06862739 · 800 planned · Pakistan
- Jul 16, 2025Boryung Pharmaceutical's first studies: 2 phase 1 studies in Diabetes MellitusNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07083401, NCT07083388
- Aug 12, 2025Phase 1 study in HealthyMerck · NCT07121959 · 14 enrolled · United States
- Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
- Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
- Dec 10, 2025aspargo-labs-inc's first studies: 2 phase 1 studies in Healthy VolunteerNew to aspargo-labs-incaspargo-labs-inc · NCT07300033, NCT07300020
- Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
- Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
- Apr 7, 2026Phase 1 study in HealthyMerck · NCT07530289 · 12 enrolled · United States
- Jun 3, 2026adium's first studies: 3 no phase studies in Bioequivalence Study in Healthy SubjectsNew to adiumadium · NCT07633054, NCT07633041, NCT07633028
- Aug 10, 20264 no phase studiesadium · NCT07763964, NCT07763951, NCT07763912 and 1 more
TargetBeta
“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 215 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07763964Bioequivalance · Mexico | – | Completed | adium | Dec 19, 2025 | 46 |
| NCT07763951Bioequivalance · Mexico | – | Completed | adium | Dec 14, 2025 | 46 |
| NCT07763912Bioequivalence · Mexico | – | Completed | adium | Dec 5, 2025 | 46 |
| NCT07763899Bioequivalance · Mexico | – | Completed | adium | Nov 30, 2025 | 46 |
| NCT07633054Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | adium | Nov 24, 2025 | 42 |
| NCT07633041Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | adium | Apr 4, 2025 | 42 |
| NCT07633028Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | adium | Apr 8, 2025 | 42 |
| NCT07530289Healthy · United States | 1 | Completed | Merck | May 23, 2026 | 12 |
| NCT07396844Fasting · Thailand | 1 | Completed | LG Chem | Jun 26, 2026 | 28 |
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | LG Chem | Feb 6, 2026 | 58 |
| NCT07300033Healthy Volunteer | 1 | Not yet recruiting | aspargo-labs-inc | Jul 15, 2026 | 24 |
| NCT07300020Healthy Volunteer | 1 | Not yet recruiting | aspargo-labs-inc | Jun 15, 2026 | 24 |
| NCT07333742Fed Conditions · South Korea | 1 | Completed | LG Chem | Nov 27, 2025 | 50 |
| NCT07222098Healthy · United States | 1 | Completed | Merck | Dec 14, 2025 | 16 |
| NCT07121959Healthy · United States | 1 | Completed | Merck | Sep 13, 2025 | 14 |
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | nabiqasim-industries-pvt-ltd | Apr 30, 2026 | 800 |
| NCT06823856Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | gedeon-richter-plc | May 21, 2025 | 64 |
| NCT06792968Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | gedeon-richter-plc | Apr 6, 2025 | 64 |
| NCT07092618Longevity · United States | 3 | Recruiting | agelessrx | Aug 2025 | 150 |
| NCT06766500Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | gedeon-richter-plc | Feb 28, 2025 | 64 |
| NCT06233201Healthy Subjects | 1 | Not yet recruiting | bio-innova-co-ltd | Jul 14, 2024 | 34 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | AstraZeneca | Feb 5, 2024 | 20 |
| NCT05823883DW6014 · Korea, Republic of | 1 | UNKNOWN | dong-wha-pharmaceutical-co-ltd | Jul 2023 | 30 |
| NCT05823870Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Mar 6, 2023 | 32 |
| NCT05874180Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Feb 1, 2023 | 31 |
| NCT05874167Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Oct 11, 2022 | 50 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05753371Drug Use · Indonesia | – | Completed | pt-pyridam-farma-tbk | Mar 24, 2022 | 24 |
| NCT05463094Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Jan 3, 2023 | 84 |
| NCT05337969To Determine Bioequivalence Under Fed Conditions | – | Completed | aet-laboratories-private-limited | Dec 2015 | 60 |
| NCT05329857To Determine Bioequivalence Under Fed Conditions | – | Completed | aet-laboratories-private-limited | Jan 2016 | 60 |
| NCT05167513Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | getz-pharma | Apr 28, 2022 | 188 |
| NCT05132023Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 2, 2019 | 26 |
| NCT05124730Pharmacokinetics · Czechia | 1 | Completed | joint-stock-company-farmak | May 29, 2021 | 44 |
| NCT05124717Pharmacokinetics · Czechia | 1 | Completed | joint-stock-company-farmak | Jul 3, 2019 | 28 |
| NCT05123781Pharmacokinetics · Czechia | 1 | Completed | joint-stock-company-farmak | Apr 17, 2019 | 28 |
| NCT05125575Pharmacokinetics · Czechia | 1 | Completed | joint-stock-company-farmak | Jan 19, 2019 | 28 |
| NCT05064488Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 10, 2021 | 40 |
| NCT04899349Breast Neoplasms · United States, Malaysia | 2 | Terminated | Novartis | May 10, 2023 | 2 |
| NCT04855513Pre-Eclampsia · Qatar | – | UNKNOWN | Hamad Medical | Apr 24, 2023 | 414 |
| NCT04841096Diabetes Mellitus, Type 2 · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Mar 15, 2024 | 162 |
| NCT04684420Diabetes Mellitus · Korea, Republic of | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 11, 2022 | 81 |
| NCT04604678COVID-19 · United States | 2 | Withdrawn | agelessrx | Aug 2021 | 0 |
| NCT04428086Solid Tumor, Adult · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 19 |
| NCT04317703Diabetes Mellitus, Type 2 · Thailand | 1 | Completed | LG Chem | Sep 5, 2020 | 40 |
| NCT04231435Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2020 | 24 |
| NCT04050098Type2 Diabetes | 1 | UNKNOWN | LG Chem | Nov 30, 2019 | 24 |
| NCT03880825Healthy Subjects · United States | 1 | Completed | cortendo-ab | May 3, 2019 | 32 |
| NCT03826602Drug-drug Interaction · United States | 1 | Completed | Pfizer | Mar 8, 2019 | 18 |
| NCT03593707Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Jan 17, 2019 | 18 |
| NCT03566810Diabetes Mellitus · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | Nov 28, 2018 | 54 |
| NCT03467971Healthy · Mexico | 1 | Completed | Merck KGaA, Darmstadt, Germany | Apr 22, 2018 | 21 |
| NCT03467945Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Apr 29, 2018 | 40 |
| NCT03458208Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation | 1 | Completed | Geropharm | Mar 2, 2017 | 18 |
| NCT03452306Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation | 1 | Completed | Geropharm | Jul 22, 2017 | 28 |
| NCT03393208Diabetes Mellitus · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | Jan 29, 2018 | 44 |
| NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil | 1 | Completed | AstraZeneca | May 22, 2018 | 284 |
| NCT03787017Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Aug 2014 | 36 |
How it is read
Names in the registry
- “Metformin”, 95 entries
- “metformin”, 33 entries
- “Metformin XR”, 11 entries
- “Fenofibrate /Metformin”, 6 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: EFB0027.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 162 studies
- Diabetes Mellitus, 17 studies
- Obesity, 3 studies
- Fasting, 3 studies
- Polycystic Ovary Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.